Latest From Nevro Corp.
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
Abbott won US FDA approval for its Proclaim XR spinal cord stimulator. The device offers lower-dose and recharge-free neurostimulation for patients with chronic pain with a battery life for up to 10 years.
Chronic pain treatment company Nevro has filed suit against rival Stimwave Tech alleging patent infringement.
- Implantable Devices
- Therapeutic Areas
- Neurology, Nervous System
- NBI Development Inc.
- North America
- Parent & Subsidiaries
- Nevro Corp.
- Senior Management
D. Keith Grossman, PhD, Pres. & CEO
Andrew Galligan, CFO
David Caraway, MD, PhD, CMO
Patrick Schmitz, VP, Operations
Niamh Pellegrini, Chief Commercial Officer
Donald A Middlebrook, VP, Clinical, Reg. & Quality
- Contact Info
Phone: (650) 251-0005
1800 Bridge Parkway
Redwood City, CA 94065
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.